NOVARTIS

Novartis posts a win, Roche a flop in skin cancer trials

Novartis posts a win, Roche a flop in skin cancer trials

Published 10/09/2017

Swiss drugmaker Novartis notched a trial win for its drug cocktail against skin cancer on Monday, while a rival treatment from Roche with slipping sales failed in a separate study with a similar patient group. [more…]

Novartis names drugs chief as CEO to deliver return to growth

Novartis names drugs chief as CEO to deliver return to growth

Published 04/09/2017

Novartis (NOVN.S) CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth. [more…]

Novartis hopeful for novel heart drug, despite `modest` benefit

Novartis hopeful for novel heart drug, despite `modest` benefit

Published 27/08/2017

Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine's limited benefits. [more…]

Novartis wins European approval for biosimilar version of Roche`s MabThera

Novartis wins European approval for biosimilar version of Roche`s MabThera

Published 19/06/2017

Swiss drugmaker Novartis on Monday said it had won European approval for its biosimilar version of Roche's blockbuster Rituxan as the crosstown rivals go head-to-head on a drug to treat blood cancers and immunological diseases.

[more…]

South Korea to fine Novartis unit over unfair drug promotions

South Korea to fine Novartis unit over unfair drug promotions

Published 08/06/2017

FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo

South Korea's antitrust regulator said it would fine Novartis' local unit 500 million won ($444,089) for alleged unfair promotions, in another setback for the Swiss drugmaker that was fined earlier this year over kickbacks to doctors.

[more…]

Novartis says U.S. regulator grants speedy review of CAR-T cell therapy

Novartis says U.S. regulator grants speedy review of CAR-T cell therapy

Published 30/03/2017

FILE PHOTO: The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland, January 25, 2017. REUTERS/Arnd Wiegmann/File Photo

Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its review of the Swiss drugmaker's CTL019 therapy for young patients with B-cell acute lymphoblastic leukemia.

[more…]

Novartis wins CHMP nod for drug combo against some lung cancers

Novartis wins CHMP nod for drug combo against some lung cancers

Published 24/02/2017

The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann

Swiss drugmaker Novartis's drugs Tafinlar and Mekinist edged closer to approval in Europe to be used together against a type of lung cancer after a key committee on Friday published a recommendation to expand the combination's indications.

[more…]

Novartis cancer drug Zykadia gets FDA priority review

Novartis cancer drug Zykadia gets FDA priority review

Published 23/02/2017

The logo of Swiss drugmaker Novartis AG is seen at its headquarters in Basel, Switzerland January 25, 2017. REUTERS/Arnd Wiegmann

The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis drug Zykadia as a first-line treatment for some lung cancer patients, the Swiss drugmaker said on Thursday.

[more…]

Novartis eye drug franchise takes hit with failed Fovista studies

Novartis eye drug franchise takes hit with failed Fovista studies

Published 12/12/2016

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel, Switzerland October 22, 2013. REUTERS/Arnd Wiegmann/File Photo

Swiss drugmaker Novartis's bid to bolster its eye drug portfolio suffered a setback on Monday when it announced combining Lucentis with Fovista in patients with neovascular age-related macular degeneration (nAMD) did not produce better outcomes than treatment with Lucentis alone.

[more…]

Novartis says 82 percent of leukemia patients in remission after CAR-T

Novartis says 82 percent of leukemia patients in remission after CAR-T

Published 05/12/2016

A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. REUTERS/Vivek Prakash/File Photo

An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday.

[more…]